KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Tax Provisions: 2009-2024

Historic Tax Provisions for Alnylam Pharmaceuticals (ALNY) over the last 12 years, with Dec 2024 value amounting to -$99.2 million.

  • Alnylam Pharmaceuticals' Tax Provisions fell 516.75% to -$12.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$75.5 million, marking a year-over-year decrease of 776.59%. This contributed to the annual value of -$99.2 million for FY2024, which is 1575.36% down from last year.
  • As of FY2024, Alnylam Pharmaceuticals' Tax Provisions stood at -$99.2 million, which was down 1,575.36% from $6.7 million recorded in FY2023.
  • Over the past 5 years, Alnylam Pharmaceuticals' Tax Provisions peaked at $6.7 million during FY2023, and registered a low of -$99.2 million during FY2024.
  • Moreover, its 3-year median value for Tax Provisions was $4.2 million (2022), whereas its average is -$29.4 million.
  • Its Tax Provisions has fluctuated over the past 5 years, first spiked by 512.21% in 2022, then slumped by 1,575.36% in 2024.
  • Alnylam Pharmaceuticals' Tax Provisions (Yearly) stood at $2.7 million in 2020, then plummeted by 74.64% to $680,000 in 2021, then soared by 512.21% to $4.2 million in 2022, then spiked by 61.54% to $6.7 million in 2023, then slumped by 1,575.36% to -$99.2 million in 2024.